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Summary. Background: Hemostasis requires a balance between procoagulant and anticoagulant factors. Hemophiliacs bleed because of a procoagulant deficiency. Targeted reduction in the activity of endogenous anticoagulant pathways is currently being investigated as a means of improving hemostasis in hemophilia. Protein Z (PZ) is a cofactor that serves as a catalyst for PZ-dependent protease inhibitor (ZPI) inactivation of activated factor X at phospholipid surfaces. Objectives: To evaluate the effects of PZ or ZPI gene deletion in hemophilic mice, and of blocking PZ in human hemophilic plasma. Methods: A tail vein rebleeding assay (TVRB) was developed on the basis of the serial disruption of clots forming over a period of 15 min following tail vein laceration in an anesthetized mouse. Wild-type (WT)/FVIII knockout FVIIIKO, PZ knockout PZKO/FVIIIKO and ZPI knockout ZPIKO/FVIIIKO mice were evaluated in this model, and their plasmas were tested in thrombin generation assays. A mAb against PZ was evaluated in human hemophilic plasma thrombin generation assays. Results: The numbers of clot disruptions (mean AE standard error of the mean) in the TVRB were: 4.0 AE 0.9 for WT/
Introduction
Ongoing studies are evaluating the therapeutic potential of suppressing specific natural anticoagulant processes to ameliorate bleeding in individuals with hemophilia. Targeted anticoagulants include tissue factor pathway inhibitor (TFPI), antithrombin, activated protein C (PC), and protein S (PS) [1] [2] [3] [4] . This approach appears to be most appropriate for prophylactic therapy with the goal of improving the clinical hemophilic phenotype from severe (< 1% factor VIII), which is associated with spontaneous bleeding, to mild (5-40% FVIII), in which hemorrhage is uncommon in the absence of trauma or surgical procedures. Such non-FVIII replacement-based therapy: (i) would not be associated with the development of FVIII inhibitors; (ii) could provide prophylactic treatment for patients with or without FVIII inhibitors; and (iii) would greatly facilitate prophylactic treatment if agents with prolonged effects and subcutaneous delivery were shown to be efficacious and of low thrombotic risk.
Another endogenous anticoagulant pathway involves protein Z (PZ) and PZ-dependent protease inhibitor (ZPI). PZ is a 62-kDa vitamin K-dependent cofactor [5] that serves as a catalyst [6] to dramatically enhance activated FX (FXa) inhibition by the 72-kDa serpin ZPI (serpinA10) at phospholipid surfaces [7, 8] . The PZ-dependent amplification of the inhibition of FXa by ZPI involves the binding of the Cterminal pseudocatalytic domain of PZ to ZPI, and the binding of the N-terminal c-carboxyglutamic acid (Gla) domain of PZ and the Gla domain of FXa at the phospholipid surface [6, [9] [10] [11] . Following the interaction of ZPI with FXa, PZ is released from the inhibitory complex. In the absence of PZ, ZPI also inhibits activated FXI (FXIa) [12] , and kinetic studies suggest that it is the most potent known inhibitor of FXIa in plasma [13] . In normal individuals, the ranges of PZ (15-233%) and ZPI (33-191%) ), respectively [14] . PZ circulates bound to ZPI in plasma [15] .
The in vivo role of the PZ-ZPI anticoagulant pathway appears to be less important than that of the other endogenous anticoagulant pathways. In people without hemophilia, modest deficiency of TFPI, antithrombin, PC or PS is associated with an increased risk of thrombosis, whereas a role for PZ or ZPI deficiency in human thrombosis has not been established [14, [16] [17] [18] [19] . In mice with normal levels of FVIII, gene deletion of TFPI, antithrombin, PC or PS causes death in utero or in the perinatal period from thrombosis, disseminated intravascular coagulation, and consumptive coagulopathy [20] [21] [22] [23] [24] . Concomitant hemophilia does not rescue TFPI-deficient [25] or antithrombin-deficient [26] mice, but does rescue PS-deficient mice [4] . PS knockout/FVIII knockout (FVIIIKO) mice, however, develop vascular thrombosis and disseminated intravascular coagulation when FVIII replacement therapy is administered [4] . PZ and ZPI genedeleted mice with normal levels of FVIII are healthy.
Here, in proof-of-concept studies, we examined the effects of inhibition of the PZ-ZPI anticoagulant pathway on hemostasis in a mouse hemophilia model, and thrombin generation in mouse and human hemophilic plasma.
Study design

Mice
C57Bl/6N (B6) mice were from Charles River (Willington, MA, USA), and B6;129S-F8 tm1Kaz /J (FVIIIKO) mice on a C57Bl/6J-129S4/SvJae genetic background were from Jackson Laboratories (Bar Harbor, ME, USA). PZ and ZPI gene-deleted mice [27, 28] had been backcrossed onto the B6 background (N > 10). After appropriate breeding, offspring from PZ(+/À)/FVIIIKO matings and ZPI(+/À)/FVIIIKO matings were tested. Results obtained in PZ(+/+)/FVIIIKO and ZPI(+/+)/FVIIIKO mice did not differ detectably, and these offspring are referred to collectively as wild-type (WT)/FVIIIKO mice. The Washington University Animal Studies Committee approved all mouse experiments.
Tail vein rebleeding assay (TVRB)
The investigator performing the assay was blinded to genotype and treatments of the mice. A mouse was anesthetized with a 5 lL g À1 intraperitoneal injection of a solution containing ketamine (10 mg mL
À1
) and dexmedetomidine (0.1 mg mL À1 ), and placed on a 37°C
warming plate. At the tail diameter of 2.25 mm, a #11 scalpel (Medi-Cut; Dynarex Corp., Orangeburg, NY, USA) was used to make a horizontal incision across a lateral tail vein to the depth of the sharpened bevel (~1 mm), and a timer was started. The position of the mouse was adjusted to immerse the tail in 37°C 0.85% NaCl in a hand-held test tube. The test tube was manipulated and replaced as needed to prevent the shed blood from obscuring the incision site. When bleeding stopped, the incision was wiped firmly with a tissue to disrupt the clot and restart bleeding, and the tail was once again immersed. This was repeated for 15 min, and the times between and the total number of clot disruptions were recorded. The anesthetized mice were killed following completion of the assay. Human recombinant FVIII (rFVIII) (Hexilate FS; CSL Behring LLC, King of Prus-
HEPES, and 2 mg mL À1 bovine serum albumin (pH 7.4) (HSA), was administered at various concentrations to mice by retro-orbital infusion (2.5 lL g À1 ) 3 min before testing. Plasma rFVIII levels following infusion were estimated on the assumption of a murine plasma volume of 50 mL kg
. Male and female mice from 20.1 g to 30.7 g in weight were used for the TVRB experiments.
Survival following tail transection
The mouse was anesthetized short-term with isoflurane when its tail was transected 10 mm from the tip with a #11 scalpel. The mouse awoke in its cage and was monitored carefully for 16 h. The investigator was blinded to mouse genotype. Any mouse showing substantial inactivity, a hunched posture, ruffled hair or inability to right itself was killed under anesthesia and recorded as a non-survivor.
Proteins/plasmas
PZ and FXa were from Enzyme Research Laboratories (South Bend, IN, USA). ZPI was isolated as previously described [7] . Anti-human PZ mAb2306.BF12.1 (anti-PZ mAb) was produced and purified with standard methods [15] . This IgG antibody recognizes an epitope in the Cterminal pseudocatalytic domain of PZ [29] . Mouse tissue factor (mTF) was prepared as a saline extract of brain. An anesthetized male B6 mouse was perfused with 0.1 mol L À1 NaCl and 0.02 mol L À1 HEPES (pH 7.4) (HS), and the brain was removed and rinsed with HS. Following homogenization in 5 mL of HS (Tekmar, Mason, OH, USA), the mixture was allowed to settle in a test tube at 37°C for 10 min, and the supernatant was harvested and stored frozen at À 80°C in small aliquots. The mTF concentration in the preparation was 2.1 nmol L À1 (Mouse Tissue Factor ELISA; Abcam, Cambridge, UK). A sample was thawed and briefly sonicated prior to use in thrombin generation assays (TGAs). Mouse blood (360 lL) was drawn from the inferior vena cava of an anesthetized mouse into 40 lL of 3.8% sodium citrate; 20 lL of 1 mg mL À1 corn trypsin inhibitor (CTI) (Enzyme Research Laboratories) was added; and plasma was obtained by centrifugation (5000 9 g for 5 min) and stored at À 80°C until use. Human hemophilic plasma with < 1% FVIII activity was from George King Bio-Medical (Overland Park, KS, USA). Human tissue factor (hTF) was from Dade Innovin (Siemens Healthcare, Tarrytown, NY, USA) and assumed to be at a concentration of 6 nmol L À1 when prepared as recommended.
Anti-PZ mAb inhibition of PZ-ZPI inactivation of FXa
The ability of the anti-PZ mAb to inhibit the function of PZ was tested in a purified system as previously described [7] . ) and variable concentrations of PZ (0-32 nmol L À1 ) in the assay in the absence of the anti-PZ mAb.
TGA
Assays were performed in a 96-well microtiter plate with final volumes of 120 lL per well. Data were collected every 30 s for 90 min in a Fluoroskan Ascent instrument (Thermo Electron Corp., Vantaa, Finland) set at 37°C. Data were analyzed with an in-house program developed as described previously [30] .
Mouse assay. Twenty microliters of HSA containing no or serial two-fold dilutions of rFVIII (starting at 2 U mL À1 ) was added to 20 lL of plasma with CTI (collected as described above 
Statistical analysis
One-way ANOVA with the Student-Newman-Keuls post hoc test was used for multiple comparisons, and a two-sided Fisher's exact test was used for paired comparisons.
Results
TVRB
The mouse has been used extensively to develop models of human disease. Tail tip transection with the measurement of bleeding time or blood loss has frequently been utilized as a method for assessing hemostasis in these murine models and to determine the hemorrhagic effects of pharmaceutical agents. Owing to the wide spread of results found with the tail transection method in both normal and gene-disrupted (e.g. hemophilic) mice [31] , a tail vein bleeding time (TVBT) model was introduced in 2001, in which laceration of a lateral tail vein, rather than tail transection, was used to induce bleeding [32] . The TVBT is sensitive to murine genetic background, aspirin and heparin treatment, a IIb b 3 deficiency [32] , and other platelet and coagulation inhibitors [33, 34] , but not vascular smooth muscle cell tissue factor deficiency [35] . An important observation in the original TVBT report was that recurrence of hemorrhage consistently develops in FVIII-deficient and FIX-deficient mice after the initial cessation of bleeding in the TVBT assay [32] . This rebleeding phenomenon occurred predominantly when the mice awoke from the anesthetic, became active, and began attending to the tail wound. Recurrent bleeding was not detected in FXI or carboxypeptidase B 2 gene-deleted animals. Consequently, the incidence of rebleeding, survival or delayed blood loss of hemophilic mice following tail vein transection has been used to assess the efficacy of coagulation factor replacement products in murine preclinical studies [36] [37] [38] [39] .
In 2008, Whinna developed a saphenous vein injury model to measure rebleeding in the mouse [40] . Clots that formed at the wound site were serially disrupted over a 30-min period, and the total number of clot disruptions was recorded [40, 41] . In the current study, the serial disruption approach was applied to the original TVBT assay [32] to produce a TVRB. In the TVRB, the numbers of clot disruptions (mean AE standard error of the mean [SEM]) were 25.8 AE 0.7 for B6 control mice and 6.8 AE 0.7 for FVIIIKO mice (Fig. 1A) . B6 control mice had relatively consistent bleeding times following each clot disruption. In contrast, bleeding times in FVIIIKO mice tended to become prolonged with successive disruptions, and, frequently, bleeding simply failed to stop after a few disruptions. To validate the TVRB, an FVIII doseresponse experiment was performed in FVIIIKO, mice and demonstrated a significant relationship (P < 0.0001) between estimated plasma rFVIII levels and the number of disruptions in the TVRB (Fig. 1B) .
PZ or ZPI deletion improves hemostasis and plasma thrombin generation in hemophilic mice
In the TVRB, the numbers of clot disruptions (mean AE SEM) for littermate mice were: 4.0 AE 0.9 for WT/FVIIIKO mice; 15.2 AE 1.1 for PZ knockout (PZKO)/FVIIIKO mice; 14.7 AE 1.2 for ZPI knockout (ZPIKO)/FVIIIKO mice; and 23.8 AE 1.1 for WT/ FVIIIKO mice supplemented with 100% FVIII (Fig. 2A) . The differences between all groups were statistically significant (P < 0.001) except for PZKO/FVIIIKO versus ZPIKO/FVIIIKO mice. Deletion of PZ or ZPI produced results in the TVRB similar to those obtained with 15% rFVIII in hemophilic mice (Fig. 1B) Pooled plasma (n = 5) from PZKO/FVIIIKO, ZPIKO/ FVIIIKO and WT/FVIIIKO mice and the last of these supplemented with 0-100% rFVIII was evaluated with the TGA (Fig. 2B) . Peak thrombin generation and the endogenous thrombin potential (ETP) in PZKO/ FVIIIKO and ZPIKO/FVIIIKO plasmas were similar to those in WT/FVIIIKO plasma supplemented with 15% and 20% FVIII, respectively. These results are consistent with the in vivo effects of PZ and ZPI gene deletion on the bleeding of FVIIIKO mice in the TVRB.
PZ inhibition improves thrombin generation in human hemophilic plasma
In the absence of a functional assay for PZ in plasma, the ability of the anti-PZ mAb to inhibit the inactivation of FXa by PZ-ZPI in the presence of phospholipids and calcium ions was tested in a system using purified components (Fig. 3A) . At 2 mg mL À1 , the anti-PZ mAb produced 98% inhibition of PZ activity. The effect of the anti-PZ mAb was compared with results obtained with various levels of FVIII supplementation in pooled hemophilic plasma (n = 4) and the four individual hemophilic plasmas by use of the TGA (Fig. 3B,C) . Under the test conditions, the anti-PZ mAb at 2 mg mL À1 increased the peak thrombin generation and the ETP to degrees equivalent to those obtained with 12% and 20% rFVIII, respectively.
Discussion
This study demonstrates that complete (by gene deletion) or near-complete (by anti-PZ mAb treatment) suppression of the PZ-ZPI anticoagulant pathway enhances coagulation in hemophilia A. The effect of extensive reduction of PZ-ZPI-dependent inhibition of FXa is modest and limited, but is nevertheless sufficient to significantly improve hemostasis in hemophilic mice. The results of the plasma TGAs in PZ and ZPI gene-deleted hemophilic mice and in human hemophilic plasma after PZ inhibition by the anti-PZ mAb were comparable to those obtained with 15% FVIII. It is not established, however, whether achieving the same enhancement in in vitro TGAs by distinct mechanisms (i.e. suppression of an anticoagulant pathway versus FVIII replacement) will necessarily translate into the same in vivo hemostatic effect. In this regard, however, it is notable that PZ or ZPI deletion in hemophilic mice was as effective as~15% FVIII replacement in both the in vitro TGA and the in vivo TVRB. A level of 15% FVIII is generally associated with a mild phenotype in hemophilic patients, although this relationship is not absolute [42, 43] .
The anti-PZ mAb used in our experiments recognizes an epitope in the C-terminal pseudocatalytic domain of PZ [29] . This PZ domain plays a critical role in the tight binding (
) of PZ to ZPI and its circulation in plasma in a complex with ZPI [6, [9] [10] [11] . Thus, the low potency of this mAb probably, in part, reflects the requirement for it to compete with ZPI for PZ binding. Among the vitamin K-dependent coagulation proteins, PZ is unique in that it associates (and dissociates) much more slowly with phospholipid surfaces (K d = 170 nmol L
À1
) in the presence of calcium ions [44] . This slow interaction of PZ with phospholipids is rate-limiting for both the interaction of PZ alone and the interaction of the PZ-ZPI complex with FXa on phospholipid surfaces [6, 7] . Thus, an agent designed to interfere with the binding of PZ and the PZ-ZPI complex with phospholipid surfaces may be a considerably more potent inhibitor of PZ function than the mAb used in our studies. An alternative approach, of course, would be small interfering RNA depression of PZ levels.
Clinical studies have not established a low level of PZ or ZPI as a thrombotic risk factor, and PZ and ZPI genedeleted mice (with normal levels of FVIII) are healthy. Nevertheless, prothrombotic effects of PZ and ZPI gene deletion can be detected in certain mouse models, with that of ZPI deficiency being greater than that of PZ deficiency [27, 28] . This presumably reflects the fact that ZPI directly inhibits FXIa as well as producing PZ-dependent inhibition of FXa [12, 13] . Therefore, at least with regard to reducing the risk of thrombosis with FVIII replacement therapy for breakthrough bleeding in hemophilia, targeting PZ, rather than ZPI, for prophylactic therapy may be more appropriate.
In summary, these studies in mice and in human plasma suggest that the modest increase in coagulation produced by inhibition of the PZ-ZPI anticoagulant pathway may be sufficient to improve the phenotype of severe hemophilia A (and presumably hemophilia B). Additional preclinical studies in other animal hemophilia models and ultimately human clinical trials would be required to confirm the beneficial hemostatic effect seen in hemophilic mice. Clinical studies would also be required to determine whether the risk of thrombosis following FVIII rescue therapy for breakthrough bleeding in hemophilic patients receiving prophylactic treatment may be less with inhibition of the PZ-ZPI pathway than with inhibition of other natural anticoagulant pathways. 
